Vivos Inc. announced that the device classification obtained from the FDA Center for Veterinary Medicine (CVM) is not limited to canine and feline sarcomas, and can be extended to a much broader population of veterinary cancers, essentially all solid tumors in animals. A review by the international law firm, Hogan-Lovells, who are premier experts on FDA matters, confirmed the broader application of the FDA’s veterinary device classification. While the FDA does not have premarket authority over veterinary devices the manufacturer is responsible for assuring that the product is safe, effective, properly labeled, and otherwise in compliance with all applicable laws and regulations. It is the company’s responsibility to maintain a strict configuration control of the product and product labeling, including applicable indications for use, to stay within the bounds of the FDA regulations.